Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
Nevro Corp. (NYSE: NVRO), a global medical device company focused on chronic pain treatment, has announced the granting of inducement restricted stock unit awards to 21 new non-executive employees. The awards, covering 51,543 shares of Nevro's common stock, were granted on September 7, 2024, by the Compensation Committee of the Company's Board of Directors.
These awards, granted under the Nevro Corp. 2023 Inducement Award Plan, are designed to induce the new employees to accept employment with Nevro. Each award vests over a three-year period, contingent on continued employment with Nevro through each vesting date. The grants were made in accordance with the NYSE Listed Company Manual Rule 303A.08 as a material inducement to employment.
Nevro Corp. (NYSE: NVRO), un'azienda globale di dispositivi medici focalizzata sul trattamento del dolore cronico, ha annunciato l'assegnazione di premi di unità di azioni soggette a restrizioni come incentivo a 21 nuovi dipendenti non esecutivi. I premi, che coprono 51.543 azioni ordinarie di Nevro, sono stati concessi il 7 settembre 2024, dal Comitato per la Retribuzione del Consiglio di Amministrazione della Società.
Questi premi, concessi nell'ambito del Piano di Premi Incentivi Nevro Corp. 2023, sono progettati per indurre i nuovi dipendenti ad accettare un impiego con Nevro. Ogni premio si matura in un periodo di tre anni, a condizione del mantenimento dell'impiego con Nevro in corrispondenza di ciascuna data di maturazione. Le concessioni sono state effettuate in conformità con la Regola 303A.08 del Manuale delle Aziende quotate NYSE come incentivo materiale all'impiego.
Nevro Corp. (NYSE: NVRO), una empresa global de dispositivos médicos centrada en el tratamiento del dolor crónico, ha anunciado la concesión de premios de unidades de acciones restringidas como incentivo a 21 nuevos empleados no ejecutivos. Los premios, que cubren 51,543 acciones ordinarias de Nevro, fueron otorgados el 7 de septiembre de 2024, por el Comité de Compensación de la Junta Directiva de la Compañía.
Estos premios, otorgados bajo el Plan de Premios de Incentivo de Nevro Corp. de 2023, están diseñados para inducir a los nuevos empleados a aceptar empleo en Nevro. Cada premio se consolida en un período de tres años, condicionado a la continuidad del empleo en Nevro hasta cada fecha de consolidación. Las concesiones se realizaron de conformidad con la Regla 303A.08 del Manual de Empresas Cotizadas de NYSE como un incentivo material para el empleo.
Nevro Corp. (NYSE: NVRO), 만성 통증 치료에 집중하는 글로벌 의료 기기 회사가 21명의 신규 비임원 직원에게 유도 제한 주식 단위 보상을 부여했다고 발표했습니다. 이 보상은 Nevro의 보통주 51,543주에 해당하며, 2024년 9월 7일에 회사 이사회 보상위원회에 의해 부여되었습니다.
이 보상은 Nevro Corp. 2023 유도 보상 계획에 따라 부여되며, 신규 직원들이 Nevro에서 근무하기 위해 수용하도록 설계되었습니다. 각 보상은 3년 기간 동안 유지되며, 각 취득 날짜까지 Nevro에 계속 재직해야 합니다. 이 보상은 NYSE 상장 기업 매뉴얼 규칙 303A.08에 따라 고용을 위한 중요한 유도로 이루어졌습니다.
Nevro Corp. (NYSE: NVRO), une entreprise mondiale de dispositifs médicaux axée sur le traitement de la douleur chronique, a annoncé l'attribution de récompenses d'unités d'actions restreintes en tant qu'incitation à 21 nouveaux employés non cadres. Les récompenses, couvrant 51 543 actions ordinaires de Nevro, ont été attribuées le 7 septembre 2024 par le comité de rémunération du conseil d'administration de la société.
Ces récompenses, accordées dans le cadre du Plan d'attribution d'incitation de Nevro Corp. 2023, sont conçues pour inciter les nouveaux employés à accepter un emploi chez Nevro. Chaque récompense prend effet sur une période de trois ans, sous condition d'un emploi continu chez Nevro jusqu'à chaque date d'acquisition. Les attributions ont été faites conformément à la règle 303A.08 du Manuel des entreprises cotées de la NYSE comme incitation matérielle à l'emploi.
Nevro Corp. (NYSE: NVRO), ein globales Medizintechnikunternehmen, das sich auf die Behandlung von chronischen Schmerzen spezialisiert hat, hat die Vergabe von Anreiz-Aktienoptionsauszeichnungen an 21 neue nicht-executive Mitarbeiter bekannt gegeben. Die Auszeichnungen, die 51.543 Aktien des Stammkapitals von Nevro umfassen, wurden am 7. September 2024 vom Vergütungsausschuss des Vorstands der Gesellschaft vergeben.
Diese Auszeichnungen, die im Rahmen des Nevro Corp. 2023 Anreizvergabeverfahrens vergeben wurden, sollen die neuen Mitarbeiter dazu anregen, eine Beschäftigung bei Nevro anzunehmen. Jede Auszeichnung wird über einen Drei-Jahres-Zeitraum fällig, wobei die fortdauernde Beschäftigung bei Nevro bis zu jedem Fälligkeitsdatum Voraussetzung ist. Die Vergaben erfolgten gemäß der Regel 303A.08 des NYSE-Handbuchs für gelistete Unternehmen als materieller Anreiz zur Beschäftigung.
- Attraction of new talent through stock-based compensation
- Alignment of employee interests with company performance through equity grants
- Compliance with NYSE rules for inducement grants
- Potential dilution of existing shareholders' equity
- Increased share-based compensation expenses
Each award was granted as a material inducement to employment in accordance with the NYSE Listed Company Manual Rule 303A.08.
Internet Posting of Information
Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.
About Nevro
Headquartered in
Nevro recently added a minimally invasive treatment option for patients suffering from chronic sacroiliac joint ("SI joint") pain and now provides the most comprehensive portfolio of products in the SI joint fusion space, designed to meet the preferences of physicians and varying patient needs in order to improve outcomes and quality of life for patients.
Senza®, Senza II®, Senza Omnia®, and HFX iQ™ are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy™. Nevro's unique support services provide every patient with HFX Coach™ support throughout their pain relief journey and every physician with HFX Cloud™ insights for enhanced patient and practice management.
SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, 10 kHz Therapy, HFX, the HFX logo, HFX iQ, the HFX iQ logo, HFX Algorithm, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp. Patents covering Senza HFX iQ and other Nevro products are listed at Nevro.com/patents.
To learn more about Nevro, connect with us on LinkedIn, X, Facebook, and Instagram.
Investor and Media Contact:
Angie McCabe
Vice President, Investor Relations & Corporate Communications
angeline.mccabe@nevro.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-announces-new-employee-inducement-grants-under-nyse-rule-303a08-302253466.html
SOURCE Nevro Corp.
FAQ
How many shares of Nevro (NVRO) stock were granted in the inducement awards?
When were the Nevro (NVRO) inducement awards granted?
How many new employees received Nevro (NVRO) inducement awards?
What is the vesting period for Nevro's (NVRO) inducement awards?
Under which plan were Nevro's (NVRO) inducement awards granted?
